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Guidelines and Literature Review
Dimitrios Velissarisa, Vassilios Karamouzosa, Charalampos Pierrakosb, Ioanna Koniaric, 
 Christina Apostolopouloud, Menelaos Karanikolase, f
Abstract
The aim of the review was to summarize the literature over the last 
25 years regarding bicarbonate administration in out-of-hospital car-
diac arrest. A PubMed search was conducted using the terms “bicar-
bonates” and “cardiac arrest”, limited to human studies and reviews 
published in English (or at least with a meaningful abstract in Eng-
lish) in the last 25 years. Clinical and experimental data raised ques-
tions regarding the safety and effectiveness of sodium bicarbonate 
(SB) administration during cardiac arrest. Earlier advanced cardiac 
life support (ACLS) guidelines recommended routine bicarbonate 
administration as part of the ACLS algorithm, but recent guidelines 
no longer recommend its use. The debate in the literature is ongoing, 
but at the present time, SB administration is only recommended for 
cardiac arrest related to hypokalemia or overdose of tricyclic antide-
pressants. Several studies challenge the assumption that bicarbonate 
administration is beneficial for treatment of acidosis in cardiac ar-
rest. At the present time, there is a trend against using bicarbonates in 
cardiac arrest, and this trend is supported by guidelines published by 
professional societies and organizations.
Keywords: Sodium bicarbonate; Cardiac arrest; Resuscitation; Meta-
bolic acidosis
Introduction
Sodium bicarbonate (SB) administration has been considered 
an important part of treatment for severe metabolic acidosis in 
cardiac arrest, because, based on pathophysiologic considera-
tions, normalization of extracellular and intracellular pH was 
considered a meaningful endpoint of resuscitation. Correction 
of metabolic acidosis with SB was recommended by early ad-
vanced cardiac life support (ACLS) guidelines published in 
1976 [1], and SB was the medication most frequently used dur-
ing cardiac arrest until the mid-1980s [2]. However, because 
of concerns regarding potential benefit vs. harm, SB use fell 
progressively to almost no use by 1991, according to one study 
from the UK [3]. At the present time, SB administration in car-
diac arrest is controversial and matter of ongoing debate, and 
frequency of use varies greatly between medical centers [4]. 
The 2010 ACLS guidelines for adults published by the Ameri-
can Heart Association (AHA) state that “Routine use of sodium 
bicarbonate is not recommended for patients in cardiac arrest” 
(class III recommendation, based on level of evidence (LOE) 
B) [5], and these guidelines were not reviewed or revised in the 
last update published in 2015 [6]. However, ACLS guidelines 
recommend administration of SB 1 mL/kg boluses as needed 
for hemodynamic stability (adequate mean arterial blood pres-
sure) and QRS narrowing in cases of severe cardiotoxicity or 
cardiac arrest from hyperkalemia or tricyclic antidepressant 
overdose (class IIb recommendation, LOE C) [7], and this rec-
ommendation was not reviewed or revised in the last revision 
of the ACLS guidelines published in 2015 [8]. The aim of this 
review was to summarize the literature of the last 25 years re-
garding the potential benefit or harm of SB administration for 
treatment of acidosis in patients with cardiac arrest.
Literature Search Methods
We conducted a PubMed database search using the terms “bi-
carbonate” and “cardiac arrest” in the “Title” field. The search 
was conducted in March 2015, but was updated in November 
2015, in order to include the latest update of the AHA guide-
lines for cardiopulmonary resuscitation. The search was limit-
ed to articles and reviews written in English, or articles written 
in other languages but accompanied by a detailed meaningful 
abstract in English, that were published in the last 25 years. 
The bibliography from all extracted manuscripts was further 
reviewed for identification of additional relevant references 
which were included in this review.
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Literature Search Results
A retrospective study published by Roberts et al in 1990 at-
tempted to identify predictors of mortality in patients resusci-
tated from cardiac arrest, and showed that survival was only 
4.2% (10 of 238 patients) when SB was used vs. 27.8% (20 
of 72 patients) when SB was not used, and this difference 
was significant (P = 0.049). However, the authors pointed out 
that poor survival in patients who received SB could reflect 
more severe illness with presence of severe metabolic acidosis 
among patients who required SB [9].
An observational cohort study published by Stiell et al in 
1995 evaluated 529 patients who suffered cardiac arrest inside 
or outside the hospital and received epinephrine according to 
ACLS protocol guidelines. The study was conducted over a 
2-year period and used univariate and multivariate logistic re-
gression to assess the association between six ACLS drugs and 
survival at 1 h and at hospital discharge. With the exception 
of procainamide, all standard ACLS drugs, including SB, did 
not have significant association with survival. However, the 
authors noted that timing of drug administration could be an 
important factor [10].
A prospective, randomized, double-blind trial published 
by Dybvik et al in 1995 enrolled 502 adults who were resusci-
tated after out-of-hospital cardiac arrest due to asystole or ven-
tricular fibrillation and failed the first defibrillation attempt. 
The study compared outcomes in 245 patients who received 
250 mL of SB-trometamol-phosphate mixture vs. 257 patients 
who received 250 mL of 0.9% saline during resuscitation con-
ducted in accordance with ACLS guidelines, and showed that, 
although patients resuscitated after out-of-hospital cardiac ar-
rest had metabolic acidosis, buffer therapy did not improve 
outcome [11].
The benefit of medications recommended by ACLS sup-
port guidelines was questioned by a prospective cohort study 
on 773 patients resuscitated after cardiac arrest published by 
van Walraven et al in 1998. This study showed that only 269 
of 773 patients survived the first hour. Multivariate logistic re-
gression was used to calculate odds ratios (ORs) and 95% con-
fidence intervals (CIs) and showed significant association be-
tween unsuccessful resuscitation and use of epinephrine (OR: 
0.08; 95% CI: 0.04 - 0.14), atropine (OR: 0.24; 95% CI: 0.17 
- 0.35), bicarbonate (OR: 0.31; 95% CI: 0.21 - 0.44), calcium 
(OR: 0.32; 95% CI: 0.18 - 0.55), and lidocaine (OR: 0.48; 95% 
CI: 0.33 - 0.71). Despite the observed association between 
bicarbonate use and unsuccessful outcome, the authors con-
cluded that their study did not find association between ACLS 
medications, including bicarbonate and successful resuscita-
tion [12].
A review article published by Adgey and Johnston in 1999 
assessed earlier publications and concluded that use of buffer 
solutions should be limited to cardiac arrests where there is 
documented severe acidosis, and should be given blindly only 
after prolonged resuscitation, or in cardiac arrest associated 
with hyperkalemia or tricyclic antidepressant overdose [13].
Similarly, a review published by Datta et al in 1999 as-
sessed basic life support, advanced life support and post-resus-
citation care, and concluded that routine use of bicarbonates 
was not recommended in cardiac arrest [14].
A large retrospective study published by Bar-Joseph et al 
in 2002 based on the brain resuscitation clinical trial III, re-
viewed records from 2,915 patients and found a linear relation-
ship between duration of ACLS and bicarbonate use. The brain 
resuscitation clinical trial III was a multicenter randomized 
trial comparing standard vs. high-dose epinephrine during car-
diopulmonary resuscitation (CPR), while SB use was optional. 
The authors concluded that, when bicarbonate was used, it was 
probably used late, and suggested that, because of develop-
ment of severe metabolic acidosis, bicarbonate administration 
should start early [15]. However, these findings were contra-
dicted by a second retrospective study published by Bar-Joseph 
et al in 2005, which was also based on the brain resuscitation 
clinical trial III database, except it only included patients with 
out-of-hospital cardiac arrest where the time from collapse to 
initiation of ACLS was shorter than 30 min, and included data 
from 2,122 patients. The study groups included patients to 
whom SB was administered in less than 50% of CPRs and first 
epinephrine to spontaneous breathing time exceeded 10 min, 
and groups where SB was administered in over 50% of CPRs 
and first epinephrine to spontaneous breathing time was < 10 
min. Multivariate regression analysis in this dataset showed 
that earlier and more frequent use of SB was related to im-
proved chance of return of spontaneous circulation (ROSC) 
and better long-term outcome [4].
Vukmir and Katz published in 2006 the results of a pro-
spective randomized, double-blinded pre-hospital clinical trial 
that was conducted in Pennsylvania between 1994 and 1998, 
before early defibrillation by first responders was introduced 
to clinical practice. Of 874 registered potentially eligible pa-
tients with pre-hospital cardiopulmonary arrest, 792 patients 
were enrolled in the study. The primary outcome was ROSC 
or arrival to the emergency department with a pulse. The ex-
perimental group (420 patients) received 1 mEq/kg of SB af-
ter standard ACLS interventions, whereas the control group 
(372 patients) received equal volume of normal saline. Over-
all, there was no difference in survival, as 58 of 420 patients 
(13.9%) survived in the bicarbonate group, compared to 52 of 
320 (13.8%) in the control group. However, in the subgroup 
of patients with prolonged (longer than 15 min) pre-hospital 
cardiac arrest, survival was 32.8% in the bicarbonate group 
vs. 15.4% in the control group, and the difference was highly 
significant (P = 0.007) [16].
A review article published by Spohr et al in 2008 con-
cluded that only a few drugs conferred a proven benefit for 
short-term survival after cardiac arrest, and suggested that bi-
carbonates should only be administered during CPR if indicat-
ed based on arterial blood gas analysis or in cases of prolonged 
unsuccessful resuscitation [17].
A retrospective study published by Geraci et al in 2009 
reviewed medical records of 88 patients who received SB dur-
ing cardiac arrest and showed that 27 of 88 patients (31%) re-
ceived SB without arterial blood gas (ABG) data. In patients 
where ABG data were available, bicarbonate administration 
was linked to alkalemia in 16% (10 of 61) of patients. The 
authors suggested that early ABG analysis in cardiac arrest 
may help optimize pH and reduce the frequency of empiric, 
not warranted, bicarbonate use [18].
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A review from Lee in 2011 mentioned the role of drugs 
administration after effective CPR and defibrillation in the car-
diac arrest, but based on randomized trials, no drugs or combi-
nation of them have shown benefit on long-term survival [19].
A review by Williamson et al in 2012 reported that al-
though short-term outcomes after CPR have improved as result 
of the administration of code drugs, in most cases there was no 
significant benefit with regard to the final outcome [20].
A retrospective cohort study published by Weng et al in 
2013 included data from 92 patients who presented to the 
emergency department with cardiac arrest. The authors com-
pared 30 patients who received vs. 62 patients who did not 
receive SB, in an attempt to assess the effect of bicarbonate 
administration after prolonged (> 15 min) CPR. Although 
Table 1.  Clinical Studies Evaluating the Effect of Sodium Bicarbonate in Cardiac Arrest
Author Origin, year Study design Findings
Aufderheide et al [24] Wisconsin, USA, 1992 Retrospective chart review, 619 arrest pts, 
273 had ROSC
No association between SB and survival
Bar-Joseph et al [15] Pittsburgh, PA, USA, 2002 Retrospective study, 2,915 pts from brain 
resuscitation clinical trial III dataset
SB given in 54% of cases, use 
increased with ACLS duration. SB 
should probably be given earlier.
Bar-Joseph et al [4] Pittsburgh, PA, USA, 2005 Retrospective study, 2,122 pts from brain 
resuscitation clinical trial III dataset with  
ACLS lasting < 30 min
Earlier and more frequent use of SB 
associated with higher resuscitation 
rates and better long-term outcome
Bishop and 
Weisfeldt [25]
Baltimore, MD, 1976 Experimental data from seven dogs, 
clinical data from six cardiac arrest pts
SB increases PCO2, accentuates 
intracellular acidosis in poorly 
ventilated pts, may be useful 
in well-ventilated pts
Delooz and Lewi [25] Leuven, Belgium, 1989 Retrospective data analysis SB > 1 mEq/kg associated with poor  
outcome
Dybvik et al [11] Oslo, Norway, 1995 RCT, SB (245 pts) vs. 0.9% NS (257 pts) SB therapy had no effect on outcome
Geraci et al [18] Jacksonville, FL, USA, 2009 Retrospective chart review, all CPR cases 
in 2005 - 2006, 88 pts received SB
SB linked with alkalemia in 16% of pts, 
recommendation for early collection of  
ABG sample
Mattar et al [22] Los Angeles, CA, USA, 1974 Case series, 12 pts, SB in cardiac arrest Plasma osmolality > 400 mOsm/kg, 
serum Na concentrations > 200 mEq/L
Roberts et al [9] Winnipeg, Manitoba, 
Canada, 1990
Retrospective study, 326 pts Survival 4.2% (10/238) when SB given 
vs. 27.8% (20/72) when SB not given 
(P = 0.049) but SB use may reflect  
presence of severe acidosis
Stiell et al [10] Ottawa, ON, Canada, 1995 Observational cohort study, 529 pts in 2 
years received epi per ACLS guidelines
Logistic regression did not show 
association between SB and survival
Suljaga-Pechtel 
et al [27]
New York, NY, USA, 1984 Prospective observational study, 277  
arrests in 226 pts
Survival lower in pts who needed SB,  
likely due to illness severity
van Walraven [12] Ottawa, ON, Canada, 1998 Prospective cohort study, 773 pts with 
cardiac arrest, logistic regression for OR  
and 95% CI
269 of 773 pts survived the first hour. 
SB use significantly associated with  
unsuccessful resuscitation
Vukmir and Katz [16] Pittsburgh, USA, 2006 RCT, 792 patients, SB (420 pts) vs.  
placebo (372 pts)
Overall survival 13.9% (110/792), 
no difference between groups. 
Trend for improved survival with 
SB in prolonged (> 15 min) arrest
Weaver et al [28] Seattle, WA, USA, 1990 RCT, lidocaine (n = 106) vs. epi (n = 
93); historical controls (n = 132) for SB
Higher survival with SB infusion, 
which was done before the study started
Weil et al [23] Chicago, IL, USA, 1985 Cohort study, 105 cardiac arrest pts, all  
received SB
Survival lower if pH > 7.55 within 10  
min of CPR
Weng et al [21] Taiwan, 2013 Retrospective cohort, 92 pts (30 with vs.  
62 without SB)
SB did not improve rate of ROSC in 
prolonged (> 15 min) cardiac arrest
ABG: arterial blood gas; ACLS: advanced cardiac life support; CI: confidence interval; CPR: cardiopulmonary resuscitation; min: minutes; epi: epi-
nephrine; pts: patients; OR: odds ratio; RCT: randomized controlled trial; ROSC: return of spontaneous circulation; SB: sodium bicarbonate.
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patients who received bicarbonate had higher percentage of 
ROSC, regression analysis showed that bicarbonate adminis-
tration did not significantly improve the rate of ROSC in out-
of-hospital cardiac arrest [21]. The findings of all the above 
clinical studies are summarized in Table 1 [4, 9-12, 15, 16, 
18, 21-28]. Studies in the table are listed in alphabetical order 
based on the first author’s last name.
Discussion
Debate regarding the potential benefit vs. harm from admin-
istration of SB in CPR has been ongoing for decades. Bi-
carbonate administration was recommended by early ACLS 
guidelines published in 1976 [1], and this recommendation 
continued when these guidelines were updated in 1980 [29], 
but concern about potential harm made bicarbonate use in car-
diac arrest increasingly controversial in recent years. As sig-
nificant acidosis is related to serious adverse systemic effects, 
bicarbonate administration seems a reasonable intervention to 
counteract the severe metabolic acidosis caused by hypoxia, 
poor perfusion and increased lactate production in cardiac ar-
rest, in an attempt to mitigate the adverse effects of acidosis, 
improve response to exogenously administered catechola-
mines and increase venous return, thereby improving coronary 
perfusion pressure [30].
Failure of ventilation and perfusion in cardiac arrest caus-
es severe disruption of homeostasis. Tissue hypoxia from hy-
poventilation or poor perfusion leads to anaerobic metabolism 
with reduced adenosine triphosphate (ATP) generation and 
increased lactic acid accumulation, thereby resulting in met-
abolic acidosis with plasma pH < 7.20 and increased lactate 
levels [31, 32]. In addition, respiratory failure with compro-
mised ventilation reduces CO2 elimination, resulting in CO2 
accumulation and respiratory acidosis. Severe combined meta-
bolic and respiratory acidosis and impaired oxygen tissue de-
livery result in cell damage, as evidenced by cardiac dysfunc-
tion from decreased myocardial contractility, hypotension, and 
renal, hepatic and central nervous system injury that can pro-
gress to multi-organ failure. Because of concerns regarding the 
deleterious effects of acidosis, clinicians have used bicarbo-
nates as buffer to offset the high acid production, in an attempt 
to help the body restore normal homeostasis in cardiac arrest.
Data published in the 1970s raised concerns that SB ad-
ministration during cardiac arrest can worsen the outcome af-
ter cardiac arrest and emphasized the adverse effects of bicar-
bonates, including increased osmolality [22]. These concerns 
were supported by experimental animal studies showing that 
administration of SB can have adverse effects in dogs with hy-
poxic lactic acidosis [33], and by clinical data showing that 
patients with cardiac arrest who received SB in accordance 
with then current ACLS guidelines had sharply lower survival 
if pH > 7.55 in the first 10 min after resuscitation started [23]. 
These arguments were rebutted in a review published in 1987 
by Narins and Cohen entitled “Bicarbonate therapy for organic 
acidosis: the case for its continued use” [34]. However, newer 
data from experiments in pigs showed that hypertonic buffer 
solutions in the absence of vasopressors can reduce coronary 
perfusion pressure below critical thresholds during cardiac 
arrest and CPR, and may adversely affect outcome [35]. In 
contrast, an experimental study published by Liu et al in 2002 
showed that administration of bicarbonate buffer solution 
promoted cerebral reperfusion and mitigated cerebral acido-
sis after restoration of spontaneous circulation in piglets [36]. 
Similarly, data from experiments with CPR in rats suggested 
that administration of SB or other buffer solutions can improve 
survival by ameliorating post-arrest myocardial dysfunction 
[37]. However, despite encouraging experimental data, con-
cerns about possible detrimental effects of SB administration 
in cardiac arrest remain.
Few human studies have examined the benefits of bicar-
bonate administration in cardiac arrest, and most of them are 
dated before 1990, at a time when SB administration was rou-
tine during CPR, even though the acid-base status of patients 
was not known in the majority of cases. However, that practice 
has changed over the years due to concerns about adverse ef-
fects of bicarbonate administration and the fact that published 
clinical studies failed to show specific benefits from their use 
[11, 24, 25, 38].
Published data in recent years suggest that SB administra-
tion can have deleterious effects during cardiac arrest, includ-
ing increased intracellular acidosis, reduced cardiac output, 
shift of the oxygen dissociation curve to the left, with increased 
affinity of hemoglobin for oxygen resulting in reduced oxygen 
tissue release, hypernatremia and hyperosmolarity [39]. As in-
creased blood and tissue CO2 concentration leads to worsening 
of tissue acidosis in major organs, including the heart, possibly 
contributing to cardiac dysfunction, it may be detrimental to 
cardiac resuscitation [26, 40-43].
In response to concerns raised by these studies, routine use 
of SB in cardiac arrest has been discouraged, and the AHA has 
deemphasized its use in the ACLS algorithms [5]. The main 
goal in cardiac arrest treatment is to intervene as early as pos-
sible, with emphasis on early activation of the emergency re-
sponse system, early initiation of CPR and early defibrillation, 
in an attempt to improve outcome. Drug administration still 
has a role in attempts to improve organ perfusion during CPR, 
facilitate electrical defibrillation, reduce myocardial irritabil-
ity, terminate malignant ventricular arrhythmias, minimize 
metabolic derangements and protect the brain from the effects 
of ischemia [44].
Buffering solutions other than SB have also been used to 
correct the metabolic acidosis during cardiac arrest. A review 
published in 1998 by Bjerneroth reported that different alka-
line buffers have been used, but have not shown any benefit 
because of numerous deleterious effects [45]. Tribonat, a mix-
ture of THAM, acetate, SB and phosphate, has been proposed 
as suitable alternative to conventional buffer solutions. A re-
view published by Bjerneroth in 1999 assessed 76 publications 
and, although it did not find improvement in overall survival, 
it suggested that Tribonat may be superior compared to previ-
ously used buffer solutions in cases where administration of an 
alkalinizing agent is indicated [46].
Some studies have suggested a beneficial role for bicarbo-
nate in the treatment of metabolic acidosis associated with car-
diac arrest of prolonged duration, while other studies showed 
that bicarbonate administration may be counter-productive 
because it increases tissue and central venous blood carbon di-
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oxide tension. Decisions regarding bicarbonate administration 
should therefore be based on central venous blood gas analysis 
[47]. Historically, a report by Stewart in 1964 described 12 
cases of cardiac arrest and, although it showed that correction 
of metabolic acidosis increased the chances of successful treat-
ment, it also suggested that bicarbonate administration is not 
warranted in all cardiac arrest cases [48]. A retrospective study 
published by Aufderheide et al in 1992 reviewed data from 
3 years of clinical experience with use of SB in 273 patients 
successfully resuscitated from cardiac arrest, and assessed the 
potential harms from bicarbonate use. The Aufderheide study 
showed that 2% (four of 215) of patients who received SB had 
hypernatremia, but there was no difference with regard to al-
kalosis, and because of study design limitations, the authors 
could not determine the influence of bicarbonate use on sur-
vival [24]. Also a review by Vukmir et al published in 1996 
analyzed all studies before that time showing that six of nine 
studies reported some prolongation of survival time after car-
diac arrest, with one study reporting worse outcome and two 
studies showing no effect of bicarbonate on survival, but most 
of these studies were uncontrolled [30]. A brief review pub-
lished by Professor Adgey in “Heart” in 1998 suggested that, 
based on available evidence, the mainstay for maintenance of 
acid-base balance in cardiac arrest is adequate alveolar ventila-
tion. The review recommended that treatment with SB should 
be reserved for cardiac arrest patients in one of the following 
four groups: 1) severe acidosis with arterial pH < 7.1 and base 
excess < 10), 2) patients with prolonged (> 10 - 20 min) car-
diac arrest, 3) cardiac arrest related to hyperkalemia, or 4) car-
diac arrest related to overdose of tricyclic antidepressants [39].
Although SB use has been part of standard therapy for 
treatment of acidosis in cardiac arrest, data published over the 
last 25 years do not support its use. The AHA revised the ACLS 
guidelines since the 2000 edition of standards and guidelines 
for CPR and emergency cardiac care (ECC), so that SB ad-
ministration is only advised at the discretion of the physician 
directing the resuscitation. In cases where clinicians choose 
to administer bicarbonates, SB should be given as IV bolus 
or by IV infusion, with standard dose being 1 mg/kg of body 
weight as initial dose, followed by 0.5 mg/kg every 10 min 
for the duration of the arrest. A 50-mL bolus of SB will raise 
serum pH approximately 0.1 of a pH unit [7]. The 2010 revised 
AHA guidelines for CPR and ECC emphasize that acidosis and 
acidemia are dynamic processes resulting from the absence of 
blood flow in cardiac arrest [5], therefore high quality CPR and 
early defibrillation in attempt to restore spontaneous circula-
tion are the best methods to restore acid-base balance, with ad-
ditional benefit gained by ventilation. The majority of studies 
cited in these guidelines showed poor outcomes and no benefit 
from bicarbonate administration, while only two studies dem-
onstrated increased ROSC and survival to hospital discharge. 
In addition, the AHA 2010 ACLS guidelines mentioned sig-
nificant potential adverse effects related to bicarbonate admin-
istration during cardiac arrest, including inactivation of simul-
taneously administered catecholamines, reduction of systemic 
vascular resistance, hypernatremia, hyperosmolality and extra-
cellular alkalosis despite intracellular PCO2 excess [7].
Because of the above reservations, current ACLS guide-
lines recommend bicarbonate administration only in cases of 
cardiac arrest related to hyperkalemia or tricyclic antidepres-
sant overdose [7]. Clinicians can repeat the bicarbonate dose 
according to patients’ clinical status or based on results of 
blood gas analysis. Alternative, non-CO2 generating buffers, 
such as THAM and Tribonate, have potential for minimizing 
the adverse effects of SB, but clinical experience and outcome 
data are very limited.
Last, according to the ACLS guidelines published by the 
AHA, routine SB administration is not recommended in the 
ACLS protocol for pulseless electrical activity, and this is a 
class III recommendation, based on LOE B (limited popula-
tions evaluated, data derived from a single randomized trial or 
non-randomized studies) [5].
Conclusion
Although many studies have shown little/no benefit and per-
haps harm from administration of SB for rapid correction of 
acidemia accompanying cardiac arrest, and the latest ACLS 
guidelines published by the AHA do not recommend routine 
administration, SB is still used as part of resuscitation in car-
diac arrest. Additional research is needed to elucidate further 
the effects of SB on organ function, on the likelihood of ROSC 
and on survival in patients resuscitated from cardiac arrest. An 
objective reappraisal of the use of SB or other buffer agents 
and perhaps on an appropriate “therapeutic window” for use of 
SB in cardiac arrest patients is warranted.
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